Our demonstration that TIMP-1 pre-treatment of leukemic blasts promotes their migration towards CXCL12 support the finding of high levels of TIMP-1 in the BM of AML patients, suggesting a role for this molecule in promoting the migration of leukemic blasts and their dissemination in extramedullary site. This evidence concerns the gene CXCL12 and acute myeloid leukemia.